MX2022004937A - Inhibidores de las cinasas raf. - Google Patents
Inhibidores de las cinasas raf.Info
- Publication number
- MX2022004937A MX2022004937A MX2022004937A MX2022004937A MX2022004937A MX 2022004937 A MX2022004937 A MX 2022004937A MX 2022004937 A MX2022004937 A MX 2022004937A MX 2022004937 A MX2022004937 A MX 2022004937A MX 2022004937 A MX2022004937 A MX 2022004937A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- raf kinase
- compounds
- raf
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925596P | 2019-10-24 | 2019-10-24 | |
| US202063044898P | 2020-06-26 | 2020-06-26 | |
| PCT/US2020/057132 WO2021081375A1 (en) | 2019-10-24 | 2020-10-23 | Inhibitors of raf kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004937A true MX2022004937A (es) | 2022-07-27 |
Family
ID=75619376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004937A MX2022004937A (es) | 2019-10-24 | 2020-10-23 | Inhibidores de las cinasas raf. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11098031B1 (https=) |
| EP (1) | EP4048259A4 (https=) |
| JP (1) | JP7626910B2 (https=) |
| KR (1) | KR20220104702A (https=) |
| CN (1) | CN114845711B (https=) |
| AU (1) | AU2020371727B2 (https=) |
| BR (1) | BR112022007612A2 (https=) |
| CA (1) | CA3158530A1 (https=) |
| CL (1) | CL2022000998A1 (https=) |
| CO (1) | CO2022006712A2 (https=) |
| IL (1) | IL292424B1 (https=) |
| MX (1) | MX2022004937A (https=) |
| PH (1) | PH12022550976A1 (https=) |
| TW (1) | TWI899110B (https=) |
| WO (1) | WO2021081375A1 (https=) |
| ZA (1) | ZA202204284B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| JP7214925B2 (ja) * | 2019-12-06 | 2023-01-30 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022060996A1 (en) * | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) * | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| EP4326255A4 (en) * | 2021-04-23 | 2025-03-12 | Pierre Fabre Medicament | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
| EP4373806A4 (en) * | 2021-07-19 | 2025-06-18 | Pierre Fabre Medicament | Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride |
| WO2023061492A1 (zh) * | 2021-10-14 | 2023-04-20 | 华领医药技术（上海）有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023070053A1 (en) * | 2021-10-21 | 2023-04-27 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CA3240192A1 (en) * | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| EP4472968A1 (en) * | 2022-02-03 | 2024-12-11 | Pierre Fabre Medicament | Inhibitors of raf kinases |
| EP4486722A4 (en) * | 2022-03-02 | 2026-03-25 | Nico Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EA018551B1 (ru) | 2008-02-22 | 2013-08-30 | Айрм Ллк | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| SI3366293T1 (sl) | 2012-06-07 | 2020-08-31 | Deciphera Pharmaceuticals, Llc | Dihidronafthiridini in sorodne spojine uporabne kot kinazni inhibitorji za zdravljenje proliferativnih bolezni |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| EP3191467B1 (en) | 2014-09-12 | 2020-10-21 | Novartis AG | Compounds and compositions as kinase inhibitors |
| CN107074828B (zh) * | 2014-09-12 | 2020-05-19 | 诺华股份有限公司 | 用作raf激酶抑制剂的化合物和组合物 |
| CA3026876A1 (en) | 2016-06-10 | 2017-12-14 | Novartis Ag | Therapeutic uses of a c-raf inhibitor |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| WO2020198058A1 (en) * | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| EP4326255A4 (en) | 2021-04-23 | 2025-03-12 | Pierre Fabre Medicament | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
-
2020
- 2020-10-23 JP JP2022523904A patent/JP7626910B2/ja active Active
- 2020-10-23 BR BR112022007612A patent/BR112022007612A2/pt unknown
- 2020-10-23 PH PH1/2022/550976A patent/PH12022550976A1/en unknown
- 2020-10-23 TW TW109136965A patent/TWI899110B/zh active
- 2020-10-23 US US17/079,152 patent/US11098031B1/en active Active
- 2020-10-23 IL IL292424A patent/IL292424B1/en unknown
- 2020-10-23 EP EP20878472.8A patent/EP4048259A4/en active Pending
- 2020-10-23 AU AU2020371727A patent/AU2020371727B2/en active Active
- 2020-10-23 CA CA3158530A patent/CA3158530A1/en active Pending
- 2020-10-23 MX MX2022004937A patent/MX2022004937A/es unknown
- 2020-10-23 KR KR1020227016515A patent/KR20220104702A/ko active Pending
- 2020-10-23 CN CN202080090257.4A patent/CN114845711B/zh active Active
- 2020-10-23 WO PCT/US2020/057132 patent/WO2021081375A1/en not_active Ceased
-
2021
- 2021-03-25 US US17/213,036 patent/US12312336B2/en active Active
-
2022
- 2022-04-14 ZA ZA2022/04284A patent/ZA202204284B/en unknown
- 2022-04-21 CL CL2022000998A patent/CL2022000998A1/es unknown
- 2022-05-20 CO CONC2022/0006712A patent/CO2022006712A2/es unknown
-
2025
- 2025-04-18 US US19/183,462 patent/US20260055084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114845711A (zh) | 2022-08-02 |
| US20260055084A1 (en) | 2026-02-26 |
| US12312336B2 (en) | 2025-05-27 |
| AU2020371727A1 (en) | 2022-05-26 |
| ZA202204284B (en) | 2024-09-25 |
| CL2022000998A1 (es) | 2023-02-10 |
| CO2022006712A2 (es) | 2022-05-31 |
| KR20220104702A (ko) | 2022-07-26 |
| BR112022007612A2 (pt) | 2022-09-20 |
| AU2020371727B2 (en) | 2026-01-22 |
| TWI899110B (zh) | 2025-10-01 |
| US20210300904A1 (en) | 2021-09-30 |
| PH12022550976A1 (en) | 2023-09-25 |
| JP7626910B2 (ja) | 2025-02-05 |
| CA3158530A1 (en) | 2021-04-29 |
| EP4048259A1 (en) | 2022-08-31 |
| EP4048259A4 (en) | 2023-08-02 |
| WO2021081375A1 (en) | 2021-04-29 |
| NZ788005A (en) | 2024-10-25 |
| TW202128680A (zh) | 2021-08-01 |
| IL292424A (en) | 2022-06-01 |
| CN114845711B (zh) | 2024-10-01 |
| IL292424B1 (en) | 2026-02-01 |
| JP2022554169A (ja) | 2022-12-28 |
| US11098031B1 (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004937A (es) | Inhibidores de las cinasas raf. | |
| JOP20210244A1 (ar) | مركبات وتركيبات وطرائق لمعالجة الأمراض | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| MX375639B (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk | |
| EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| MX2019008435A (es) | Inhibidores selectivos de jak1. | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| SA522441624B1 (ar) | مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| MX2024007444A (es) | Inhibidores de cinasa met. | |
| MX2024009105A (es) | Inhibidores de las cinasas cdk4/6. | |
| MX387785B (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos. | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| DK3604304T3 (da) | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme | |
| BR112021022380A2 (pt) | Inibidores de jak | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |